Major Depressive Disorder Stocks List

Major Depressive Disorder Stocks Recent News

Date Stock Title
May 20 PFE Pfizer Wins $107.5M Verdict Against AstraZeneca Over Cancer Drug Patent Dispute
May 20 PFE Moderna and Novavax Hope for Early Launch of This Year’s Covid-19 Shots, Despite FDA Delay
May 20 PFE AstraZeneca (AZN) to Build $1.5B Cancer Drug Plant in Singapore
May 20 PFE 3 High-Yield Dividend Stocks I'm Buying Hand Over Fist
May 20 PFE 3 Reliable Dividend Stocks With Yields Above 5% You Can Buy With Less Than $100 Right Now
May 20 PFE Pfizer wins cancer drug patent case against AstraZeneca
May 19 PFE Billionaires Are Buying These High-Yield Dividend Stocks Left and Right. Should You Follow Their Lead?
May 18 PFE Cannabis Meets Prescription Drugs, Steroids And Ketamine In Schedule III: What It Means, Key Stocks To Watch
May 17 PFE 4 Stocks That Could Break Novo Nordisk, Lilly's Obesity Duopoly
May 17 PFE European Patent Office Sides with Moderna In COVID-19 Vaccine Patent Dispute With Pfizer/BioNTech
May 17 PFE Update: Market Chatter: Moderna Wins European Patent Ruling in Covid-19 Vaccine Dispute With Pfizer, BioNTech
May 17 PFE Market Chatter: Moderna Wins European Patent Ruling in Covid-19 Vaccine Dispute With Pfizer, BioNTech
May 17 PFE Pfizer Stock: Rebound Has Started (Technical Analysis)
May 17 PRAX Praxis Precision Medicines to Participate in Upcoming Investor Conferences
May 17 PFE Pfizer: Potential Double-Digit Upside Combined With High Dividend Yield
May 16 VNDA Vanda (VNDA) Rises on Positive Data From Motion Sickness Study
May 16 PFE Pfizer, AstraZeneca, Sanofi And Mainz Biomed To Uplevel Europe's Pharma Game
May 16 PFE 2 Top Growth Stocks Down 24% and 50% to Buy With $100
May 16 VNDA Vanda Pharmaceuticals reports positive data from motion sickness trial
May 16 PFE Arvinas and Pfizer Announce Updated Clinical Data from Phase 1b Trial of Vepdegestrant in Combination with Palbociclib (IBRANCE®)
Major Depressive Disorder

Major depressive disorder (MDD), also known simply as depression, is a mental disorder characterized by at least two weeks of low mood that is present across most situations. It is often accompanied by low self-esteem, loss of interest in normally enjoyable activities, low energy, and pain without a clear cause. People may also occasionally have false beliefs or see or hear things that others cannot. Some people have periods of depression separated by years in which they are normal, while others nearly always have symptoms present. Major depressive disorder can negatively affect a person's personal life, work life, or education, as well as sleeping, eating habits, and general health. Between 2–8% of adults with major depression die by suicide, and about 50% of people who die by suicide had depression or another mood disorder.The cause is believed to be a combination of genetic, environmental, and psychological factors. Risk factors include a family history of the condition, major life changes, certain medications, chronic health problems, and substance abuse. About 40% of the risk appears to be related to genetics. The diagnosis of major depressive disorder is based on the person's reported experiences and a mental status examination. There is no laboratory test for major depression. Testing, however, may be done to rule out physical conditions that can cause similar symptoms. Major depression is more severe and lasts longer than sadness, which is a normal part of life. The United States Preventive Services Task Force (USPSTF) recommends screening for depression among those over the age 12, while a prior Cochrane review found that the routine use of screening questionnaires have little effect on detection or treatment.Typically, people are treated with counseling and antidepressant medication. Medication appears to be effective, but the effect may only be significant in the most severely depressed. It is unclear whether medications affect the risk of suicide. Types of counseling used include cognitive behavioral therapy (CBT) and interpersonal therapy. If other measures are not effective, electroconvulsive therapy (ECT) may be considered. Hospitalization may be necessary in cases with a risk of harm to self and may occasionally occur against a person's wishes.Major depressive disorder affected approximately 216 million people (3% of the world's population) in 2015. The percentage of people who are affected at one point in their life varies from 7% in Japan to 21% in France. Lifetime rates are higher in the developed world (15%) compared to the developing world (11%). It causes the second most years lived with disability, after lower back pain. The most common time of onset is in a person's 20s and 30s. Females are affected about twice as often as males. The American Psychiatric Association added "major depressive disorder" to the Diagnostic and Statistical Manual of Mental Disorders (DSM-III) in 1980. It was a split of the previous depressive neurosis in the DSM-II, which also encompassed the conditions now known as dysthymia and adjustment disorder with depressed mood. Those currently or previously affected may be stigmatized.

Browse All Tags